| Basics |
XBiotech Inc. Common Stock
XBiotech Inc is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases.
|
| IPO Date: |
April 13, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$87.19M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.28 | 2.94%
|
| Avg Daily Range (30 D): |
$0.06 | 2.13%
|
| Avg Daily Range (90 D): |
$0.10 | 3.26%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.12M |
| Avg Daily Volume (30 D): |
.04M |
| Avg Daily Volume (90 D): |
.04M |
| Trade Size |
| Avg Trade Size (Sh.): |
125 |
| Avg Trade Size (Sh.) (30 D): |
84 |
| Avg Trade Size (Sh.) (90 D): |
79 |
| Institutional Trades |
| Total Inst.Trades: |
187 |
| Avg Inst. Trade: |
$1.67M |
| Avg Inst. Trade (30 D): |
$.93M |
| Avg Inst. Trade (90 D): |
$.93M |
| Avg Inst. Trade Volume: |
.12M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.6M |
| Avg Closing Trade (30 D): |
$.93M |
| Avg Closing Trade (90 D): |
$.93M |
| Avg Closing Volume: |
225.81K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-1.29
|
$-.36
|
$-.34
|
|
Diluted EPS
|
|
|
|
|
Revenue
|
$
|
$ M
|
$
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -39.41M
|
$ -10.88M
|
$ -10.51M
|
|
Operating Income / Loss
|
$ -45.17M
|
$ -13.55M
|
$ -8.75M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -47.01M
|
$ -17.06M
|
$ -11.87M
|
|
PE Ratio
|
|
|
|
|
|
|
